TY - JOUR
T1 - Impaired self-renewal and increased colitis and dysplastic lesions in colonic mucosa of AKR1B8-deficient mice
AU - Shen, Yi
AU - Ma, Jun
AU - Yan, Ruilan
AU - Ling, Hongyan
AU - Li, Xiaoning
AU - Yang, Wancai
AU - Gao, John
AU - Huang, Chenfei
AU - Bu, Yiwen
AU - Cao, Yu
AU - He, Yingchun
AU - Wan, Laxiang
AU - Zu, Xuyu
AU - Liu, Jianghua
AU - Huang, Mei Chris
AU - Stenson, William F.
AU - Liao, Duan Fang
AU - Cao, Deliang
N1 - Publisher Copyright:
©2014 AACR.
PY - 2015/3/15
Y1 - 2015/3/15
N2 - Purpose: Ulcerative colitis and colitis-associated colorectal cancer (CAC) is a serious health issue, but etiopathological factors remain unclear. Aldo-keto reductase 1B10 (AKR1B10) is specifically expressed in the colonic epithelium, but downregulated in colorectal cancer. This study was aimed to investigate the etiopathogenic role of AKR1B10 in ulcerative colitis and CAC. Experimental Design: Ulcerative colitis and CAC biopsies (paraffin-embedded sections) and frozen tissues were collected to examine AKR1B10 expression. Aldo-keto reductase 1B8 (the ortholog of human AKR1B10) knockout (AKR1B8-/-) mice were produced to estimate its role in the susceptibility and severity of chronic colitis and associated dysplastic lesions, induced by dextran sulfate sodium (DSS) at a low dose (2%). Genome-wide exome sequencing was used to profile DNA damage in DSS-induced colitis and tumors. Results: AKR1B10 expression was markedly diminished in over 90% of ulcerative colitis and CAC tissues. AKR1B8 deficiency led to reduced lipid synthesis from butyrate and diminished proliferation of colonic epithelial cells. The DSS-treated AKR1B8-/- mice demonstrated impaired injury repair of colonic epithelium and more severe bleeding, in flammation, and ulceration. These AKR1B8-/- mice had more severe oxidative stress and DNA damage, and dysplasias were more frequent and at a higher grade in the AKR1B8-/- mice than in wild-type mice. Palpable masses were seen in the AKR1B8-/- mice only, not in wild-type. Conclusions: AKR1B8 is a critical protein in the proliferation and injury repair of the colonic epithelium and in the pathogenesis of ulcerative colitis and CAC, being a new etiopathogenic factor of these diseases.
AB - Purpose: Ulcerative colitis and colitis-associated colorectal cancer (CAC) is a serious health issue, but etiopathological factors remain unclear. Aldo-keto reductase 1B10 (AKR1B10) is specifically expressed in the colonic epithelium, but downregulated in colorectal cancer. This study was aimed to investigate the etiopathogenic role of AKR1B10 in ulcerative colitis and CAC. Experimental Design: Ulcerative colitis and CAC biopsies (paraffin-embedded sections) and frozen tissues were collected to examine AKR1B10 expression. Aldo-keto reductase 1B8 (the ortholog of human AKR1B10) knockout (AKR1B8-/-) mice were produced to estimate its role in the susceptibility and severity of chronic colitis and associated dysplastic lesions, induced by dextran sulfate sodium (DSS) at a low dose (2%). Genome-wide exome sequencing was used to profile DNA damage in DSS-induced colitis and tumors. Results: AKR1B10 expression was markedly diminished in over 90% of ulcerative colitis and CAC tissues. AKR1B8 deficiency led to reduced lipid synthesis from butyrate and diminished proliferation of colonic epithelial cells. The DSS-treated AKR1B8-/- mice demonstrated impaired injury repair of colonic epithelium and more severe bleeding, in flammation, and ulceration. These AKR1B8-/- mice had more severe oxidative stress and DNA damage, and dysplasias were more frequent and at a higher grade in the AKR1B8-/- mice than in wild-type mice. Palpable masses were seen in the AKR1B8-/- mice only, not in wild-type. Conclusions: AKR1B8 is a critical protein in the proliferation and injury repair of the colonic epithelium and in the pathogenesis of ulcerative colitis and CAC, being a new etiopathogenic factor of these diseases.
UR - http://www.scopus.com/inward/record.url?scp=84927619436&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-14-2072
DO - 10.1158/1078-0432.CCR-14-2072
M3 - Article
C2 - 25538260
AN - SCOPUS:84927619436
SN - 1078-0432
VL - 21
SP - 1466
EP - 1476
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 6
ER -